EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma

Dong Hyun Kim, Jiwon Koh, Yoon Kyung Jeon, Kyeong Cheon Jung, Jungirl Seok, Eun-Jae Chung, Seong-Keun Kwon, Soon-Hyun Ahn, Bhumsuk Keam

Cancer Immunology, Immunotherapy · 24.07.2026 · 75 (11)

DOI: 10.1007/s00262-026-04504-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 24.07.2026. Verfasst von Dong Hyun Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongro-gu, Seoul, 03080, Republic of Korea. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neck dissection and adequate lymph node yield (LNY) are important in the treatment of head and neck squamous cell carcinoma (HNSCC). Cervical lymph nodes represent the primary sites for T-cell priming; however, the impact of LNY on the efficacy of immune checkpoint inhibitors (ICIs) remains unclear.

Methods

A total of 120 patients with HNSCC who relapsed after surgical resection and subsequently received ICIs were included. The association of LNY, neutrophil–lymphocyte ratio (NLR), and programmed death-ligand 1 (PD-L1) expression with ICI outcomes were evaluated.

Results

Among 120 patients, 31 underwent unilateral, 82 bilateral, and 7 no neck dissection. The median LNY was 26 (mean, 29.9; range, 0–145). PD-L1 expression was evaluated in 80 patients, 69 of whom had combined positive score ≥ 1. The low-LNY group had a higher overall response rate to ICI than the high-LNY group (42.9% vs. 16.9%, P = 0.003). Patients with high LNY had inferior PFS (median, 1.3 vs. 5.9 months; P < 0.001) and OS (median, 9.7 vs. 21.1 months; P = 0.007) compared with those with low LNY. In multivariable analysis, high LNY and high NLR were independent predictors of poor survival, whereas PD-L1 expression was not. Among patients with PD-L1–positive tumors, those with high NLR had inferior survivals compared with those with low NLR.

Conclusions

Extensive lymphatic ablation, as reflected by high LNY, may be associated with diminished ICI efficacy in relapsed HNSCC. These findings suggest that LNY warrants further investigation as a potential biomarker for ICI outcomes in patients with post-surgical recurrent HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsSquamous Cell Carcinoma of Head and NeckNeoplasm Recurrence, LocalHead and Neck NeoplasmsLymph NodesHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overLymphatic MetastasisB7-H1 AntigenNeck Dissection

Stichwörter der Autor:innen

Head and neck squamous cell carcinomaImmune checkpoint inhibitorLymph node yieldNeck dissectionNeutrophil–lymphocyte ratioPD-L1

Substanzen

Immune Checkpoint InhibitorsB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongro-gu, Seoul, 03080, Republic of Korea.
  • Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongro-gu, Seoul, 03080, Republic of Korea. bhumsuk@snu.ac.kr.

Zitieren

APA

Kim, D. H., Koh, J., Jeon, Y. K., Jung, K. C., Seok, J., Chung, E. J., Kwon, S. K., Ahn, S. H., & Keam, B. (2026). Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma. Cancer Immunology, Immunotherapy, 75(11). https://doi.org/10.1007/s00262-026-04504-x

Vancouver

Kim DH, Koh J, Jeon YK, Jung KC, Seok J, Chung EJ, et al. Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma. Cancer Immunology, Immunotherapy. 2026;75(11). doi:10.1007/s00262-026-04504-x

BibTeX
@article{Kim2026,
  author = {Kim, Dong Hyun and Koh, Jiwon and Jeon, Yoon Kyung and Jung, Kyeong Cheon and Seok, Jungirl and Chung, Eun-Jae and Kwon, Seong-Keun and Ahn, Soon-Hyun and Keam, Bhumsuk},
  title = {Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {11},
  doi = {10.1007/s00262-026-04504-x}
}
Kostenlos starten →